Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
Colorcon
McKesson
AstraZeneca

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020882

See Plans and Pricing

« Back to Dashboard

NDA 020882 describes NEURONTIN, which is a drug marketed by Pfizer Pharms and Parke Davis and is included in three NDAs. It is available from three suppliers. There is one patent protecting this drug. Additional details are available on the NEURONTIN profile page.

The generic ingredient in NEURONTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the gabapentin profile page.
Summary for 020882
Tradename:NEURONTIN
Applicant:Pfizer Pharms
Ingredient:gabapentin
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020882
Suppliers and Packaging for NDA: 020882
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEURONTIN gabapentin TABLET;ORAL 020882 NDA Parke-Davis Div of Pfizer Inc 0071-0401 0071-0401-24 100 TABLET, FILM COATED in 1 BOTTLE (0071-0401-24)
NEURONTIN gabapentin TABLET;ORAL 020882 NDA Parke-Davis Div of Pfizer Inc 0071-0513 0071-0513-24 100 TABLET, FILM COATED in 1 BOTTLE (0071-0513-24)
Paragraph IV (Patent) Challenges for 020882
Tradename Dosage Ingredient NDA Submissiondate
NEURONTIN TABLET;ORAL gabapentin 020882

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength600MG
Approval Date:Oct 9, 1998TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength800MG
Approval Date:Oct 9, 1998TE:ABRLD:Yes

Expired US Patents for NDA 020882

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Pharms NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin TABLET;ORAL 020882-001 Oct 9, 1998   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin TABLET;ORAL 020882-001 Oct 9, 1998   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin TABLET;ORAL 020882-002 Oct 9, 1998   Start Trial   Start Trial
Pfizer Pharms NEURONTIN gabapentin TABLET;ORAL 020882-001 Oct 9, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Johnson and Johnson
Merck
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.